CN101744827B - Medicinal composition for killing chicken colibacillosis and preparation method and use thereof - Google Patents
Medicinal composition for killing chicken colibacillosis and preparation method and use thereof Download PDFInfo
- Publication number
- CN101744827B CN101744827B CN2008101540726A CN200810154072A CN101744827B CN 101744827 B CN101744827 B CN 101744827B CN 2008101540726 A CN2008101540726 A CN 2008101540726A CN 200810154072 A CN200810154072 A CN 200810154072A CN 101744827 B CN101744827 B CN 101744827B
- Authority
- CN
- China
- Prior art keywords
- chicken colibacillosis
- pharmaceutical composition
- preparation
- medicinal composition
- amoxicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicinal composition for killing chicken colibacillosis, a preparation method and a use thereof, wherein the medicinal composition is prepared from the following components according to percentages by weight: 5-20% of amoxicillin, 2-3% of clavulanic acid, 6-10% of cefixime, 8-12% of fosfomycin, and accessories with left quantity. The invention is featured with scientific formulation, strong sterilization ability, low cost and convenient use; further, the medicinal composition can be directly added to animal feed or drinking water without toxic nor side effect nor medicinal residue; thus, the medicinal composition for killing chicken colibacillosis meets the standard of safe veterinary drug and ensures the safety of animal-derived food.
Description
Technical field
The invention belongs to field of veterinary, especially a kind of pharmaceutical composition of treating chicken colibacillosis and preparation method thereof, application.
Background technology
Along with the fast development of China's aviculture, large, medium and small foster fowl factory spreads all over the place at motherland's the earth, and aviculture has become the important channel that vast farmers is got rich.Meanwhile, the fowl diseases particularly colibacillosis of poultry (chicken, duck, goose) usually takes place, and has had a strong impact on further developing of aviculture.Avian colibacillosis is the general name of the several diseases that caused by dust Xi Shi escherichia coli; Comprise diseases such as escherichia coli granuloma, peritonitis, salpingitis, omphalitis, synovitis, airsacculitis, ophthalmia, yolk peritonitis; Serious to aviculture harm, in various birdss, with susceptible comparatively such as chicken, duck, goose and turkey; The chicken at various ages all can infect, and its incidence and mortality is variant because of influenced by various factors.Escherichia coli are at ubiquity everywhere such as the body surface of feedstuff, drinking-water, chicken, hatchery, couveuse, wherein in hatching egg surface, the egg, the dead germ in the hatching process and in egg separation rate higher.Primary disease all can take place chick stage, finishing period and adult laying hen, and chickling is acute sepsis, and big chicken is main with subacute or chronic infection then, makes its infection even more serious if be mixed with the influence of other pathogen or stressors.Young chicken and adult chicken, frequent and other disease of colibacillosis, for example: infectious bronchitis, newcastle, chronic respiratory tract disease, infective rhinitis, salpingitis or eyeball inflammation are concurrent.Primary disease is mainly propagated through the feedstuff and the drinking-water of hatching egg, airborne dust, pollution, all can take place throughout the year, and is rainy, sultry, wet season is multiple.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition of treating chicken colibacillosis; This pharmaceutical composition has stronger sterilizing ability; Cost is lower, and is easy to use, can directly be added in animal feed and the drinking water; Have no side effect and drug residue, meet safe veterinary drug, ensure the animal-derived food safe requirement.
Another object of the present invention is to provide a kind of preparation of drug combination method of treating chicken colibacillosis.
Another object of the present invention is to provide a kind of application of treating the pharmaceutical composition of chicken colibacillosis.
The present invention realizes through following technical scheme:
A kind of pharmaceutical composition of treating chicken colibacillosis, wherein the component of this pharmaceutical composition and percentage by weight thereof are respectively:
Amoxicillin 5-20%;
Clavulanic acid 2-3%;
Cefixime 6-10%;
Fosfomycin 8-12%;
Surplus is an adjuvant.
And the optimum percentage by weight of the component of this pharmaceutical composition is respectively:
Amoxicillin 10%;
Clavulanic acid 2.5%;
Cefixime 8%;
Fosfomycin 10%;
Adjuvant 69.5%.
And described adjuvant is wherein a kind of, perhaps two or more combination of oral glucose, anhydrous glucose, sucrose, lactose.
A kind of preparation of drug combination method of treating chicken colibacillosis, its step is following:
(1). take by weighing amoxicillin, clavulanic acid, cefixime, fosfomycin pulverizing respectively according to weight proportion, cross 80～100 mesh sieves;
(2). with the amoxicillin of sieving, clavulanic acid, cefixime and fosfomycin and adjuvant mix homogeneously, the pharmaceutical composition finished product of the chicken colibacillosis that promptly obtains medical treatment.
A kind of application of pharmaceutical composition in the medicine of preparation treatment chicken colibacillosis of treating chicken colibacillosis.
Advantage of the present invention and beneficial effect are:
1. this pharmaceutical composition is added with the amoxicillin; Lactam group hydrolysis immediately in the molecule of amoxicillin, oral back generates peptide bond; Rapid and endobacillary transpeptidase combines to make it inactivation, has cut off the unique channel that thalline relies on the synthetic glycopeptide of transpeptidase to be used for building cell wall, makes bacterial cell become spheroplast and the dissolving of breaking rapidly; Constantly the infiltration spalling is dead because of cell wall loss moisture content for thalline; The amoxicillin bactericidal action is strong, and the ability of penetration cell wall is also strong, and most of morbific G+ bacterium and G-bacterium (comprising coccus and bacillus) are all had powerful antibacterial and bactericidal action.
2. to contain clavulanic acid be beta-lactamase inhibitor to this pharmaceutical composition; Can bring into play the strong effect wide-spectrum inhibitory action to the beta-lactamase that fastbacteria produces; Clavulanic acid and amoxicillin associating; Can protect the amoxicillin not brought into play its bactericidal action, thereby play synergic effect by the beta-lactam enzyme-deactivating.
3. the cefixime that contains of this pharmaceutical composition is a third generation oral cephalosporin; Has a broad antifungal spectrum; Most enterobacteriaceae lactobacteriaceaes such as micrococcus scarlatinae, streptococcus pneumoniae, streptococcus agalactiae, gonococcus, hemophilus influenza, mora mucositis bacterium and escherichia coli, pneumobacillus are had good antibacterial activity, and cefixime is highly stable to beta lactamase, with penicillin-binding protein high affinity is arranged; Make the bacteria cell wall biosynthesis block, antibacterial is dissolved rapidly, death.
4. the fosfomycin that contains of this pharmaceutical composition can suppress the early stage synthetic of bacteria cell wall; Its molecular structure is similar with phosphoenolpyruvate; So can compete same transferring enzyme; Make synthetic being prevented of bacteria cell wall and cause bacterial death; The fosfomycin has a broad antifungal spectrum all has higher antibacterial activity to staphylococcus, escherichia coli, Serratia and Shigella etc., and bacillus pyocyaneus, Proteus, aerobacteria, pneumobacillus, streptococcus and part anaerobe are also had certain antibacterial action.
5. compatibility science of the present invention has stronger sterilizing ability, and cost is lower; Easy to use; Can directly be added in animal feed and the drinking water, have no side effect and drug residue, be a kind of pharmaceutical composition that meets safe veterinary drug, ensures the treatment chicken colibacillosis of animal-derived food safety.
The specific embodiment
The present invention further details through following examples.Need to prove: following embodiment is illustrative, is not determinate, can not limit protection scope of the present invention with following embodiment.
Amoxicillin involved in the present invention, clavulanic acid, cefixime, fosfomycin, oral glucose, anhydrous glucose, sucrose, lactose all can be bought on market and obtain.
Embodiment 1
A kind of pharmaceutical composition of treating chicken colibacillosis, wherein the component of this pharmaceutical composition and weight thereof are respectively: amoxicillin 5kg, clavulanic acid 2kg, cefixime 6kg, fosfomycin 8kg, anhydrous glucose 79kg.
A kind of preparation of drug combination method of treating chicken colibacillosis, its step is following:
(1). take by weighing amoxicillin, clavulanic acid, cefixime, fosfomycin pulverizing respectively according to weight proportion, cross 80 mesh sieves;
(2). with the amoxicillin of sieving, clavulanic acid, cefixime and fosfomycin and adjuvant mix homogeneously, the pharmaceutical composition finished product of the chicken colibacillosis that promptly obtains medical treatment.
Embodiment 2
A kind of pharmaceutical composition of treating chicken colibacillosis, wherein the component of this pharmaceutical composition and weight thereof are respectively: amoxicillin 20kg, clavulanic acid 3kg, cefixime 10kg, fosfomycin 12kg, lactose 55kg.
The step of its preparation method is with embodiment 1.
Embodiment 3
A kind of pharmaceutical composition of treating chicken colibacillosis, wherein the component of this pharmaceutical composition and weight thereof are respectively: amoxicillin 10kg, clavulanic acid 2.5kg, cefixime 8kg, fosfomycin 10kg, oral glucose 69.5kg.
The step of its preparation method is with embodiment 1.
A kind of application of pharmaceutical composition in the medicine of preparation treatment chicken colibacillosis of treating chicken colibacillosis.
In application, need the present invention is dissolved in the water, fully after the dilution, supply chicken freely to drink, every 200kg water is used 100g of the present invention, every day 2 times, logotype 3 days.
Clinical trial
1. materials and methods
Experimental animal:
5000 of Tianjin Dongli District plant 30 age in days broiler are as experimental animal, and according to incidence, clinical symptoms, typically cut open inspection and change and lab testing, making a definite diagnosis this group broiler is the escherichia coli systemic infection.
Trial drug:
(1). contain amoxicillin 10g, clavulanic acid 2.5g, cefixime 8g, fosfomycin 10g, oral glucose 69.5g among the 100g of the present invention.
(2). contain florfenicol 10g among the clean 100g of bacillus, certain animal pharmaceutical factory of effluent south produces product batch number 20061202.
EXPERIMENTAL DESIGN:
Therapeutic test: select 550 of the sick chickens of 30 ages in days that are diagnosed as the escherichia coli systemic infection, be divided into 3 groups at random, 250 of experimental grouies, 250 of medicine matched groups, 50 of blank groups.
(1). experimental group adopts the present invention's drinking-water, and every 200kg water is used 100g of the present invention, every day 2 times, logotype 3 days.
(2). the medicine matched group adopts bacillus to drink water only, and every 200kg water is with the clean 100g of bacillus, every day 2 times, logotype 3 days.
(3). the not medication of blank group.
Jumpbogroup control test: remain 4450 sick chickens, adopt the present invention to drink water, every 200kg water is with these article 100g, every day 2 times, logotype 3 days.Efficacy determination: course of treatment of administration, tracing study after 3 days.Recovery from illness: clinical symptom disappearance, each item physical signs is recovered normal (spirit, appetite, drinking-water, feces etc.).Effectively: cardinal symptom is alleviated, and each item physical signs is normal (spirit, appetite, drinking-water, feces etc.) basically.Invalid: clinical symptoms does not have and is clearly better, and perhaps worsens dead.
2 results
Therapeutic test:
To 550 sick chickens with 2 kinds of medicines respectively to its treatment of carrying out 1 course of treatment, the result shows: treatment chicken colibacillosis systemic infection, effective percentage of the present invention and cure rate all are higher than medicine matched group and blank group; Cure rate of the present invention is compared significant difference (P＜0.05) with the medicine matched group; Effective percentage of the present invention is compared difference extremely significantly (P＜0.01) with the blank group, medication effect such as following table:
| Group | Case load | The recovery from illness number | Cure rate % | Significant figure | Effective percentage % | Invalid number | Inefficiency % |
| Experimental group | 250 | ?227 | ?90.8 | ?246 | ?98.4 | ?4 | ?1.6 |
| The medicine matched group | 250 | ?167 | ?66.8 | ?193 | ?77.2 | ?57 | ?22.8 |
| The blank group | 50 | ?0 | ?0 | ?1 | ?2 | ?49 | ?98 |
Jumpbogroup control test: the 2nd day mortality rate of medication obviously descends, and just controlled death after the 3rd day, medication effect such as following table:
| Case load | The recovery from illness number | Cure rate % | Significant figure | Effective percentage % | Invalid number | Inefficiency % |
| 4450 | 3947 | ?88.7 | 4275 | ?96.1 | 175 | ?3.9 |
Claims (4)
1. pharmaceutical composition of treating chicken colibacillosis, it is characterized in that: the percentage by weight of this pharmaceutical composition component is respectively:
2. the pharmaceutical composition of treatment chicken colibacillosis according to claim 1 is characterized in that: described adjuvant is wherein a kind of, perhaps two or more combination of oral glucose, anhydrous glucose, sucrose, lactose.
3. the preparation of drug combination method of a treatment chicken colibacillosis as claimed in claim 1, it is characterized in that: the step of method for preparing is following:
(1). take by weighing amoxicillin, clavulanic acid, cefixime, fosfomycin pulverizing respectively according to weight proportion, cross 80～100 mesh sieves;
(2). with the amoxicillin of sieving, clavulanic acid, cefixime and fosfomycin and adjuvant mix homogeneously, the pharmaceutical composition finished product of the chicken colibacillosis that promptly obtains medical treatment.
4. the application of the pharmaceutical composition of a treatment chicken colibacillosis as claimed in claim 1 in the medicine of preparation treatment chicken colibacillosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101540726A CN101744827B (en) | 2008-12-15 | 2008-12-15 | Medicinal composition for killing chicken colibacillosis and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101540726A CN101744827B (en) | 2008-12-15 | 2008-12-15 | Medicinal composition for killing chicken colibacillosis and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101744827A CN101744827A (en) | 2010-06-23 |
| CN101744827B true CN101744827B (en) | 2012-05-30 |
Family
ID=42472843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101540726A Expired - Fee Related CN101744827B (en) | 2008-12-15 | 2008-12-15 | Medicinal composition for killing chicken colibacillosis and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101744827B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200909787A2 (en) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. |
| US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
| NZ702087A (en) | 2012-06-29 | 2016-12-23 | Bayer Animal Health Gmbh | Pharmaceutical compositions and treatment of mastitis |
| CN107773759A (en) * | 2016-08-31 | 2018-03-09 | 瑞普（天津）生物药业有限公司 | Purposes of the gravel in drug bioavailability is improved |
-
2008
- 2008-12-15 CN CN2008101540726A patent/CN101744827B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 张秋民.磷霉素钙水溶粉对鸡大肠杆菌病的治疗试验.《中国饲料》.2001,(第21 期),p.14-15. * |
| 陈志华.禽大肠杆菌病的药物防制.《动物科学与动物医学》.2003,第20 卷(第1 期),p.32左栏第一段,p.33左栏第2、3段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101744827A (en) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hofacre et al. | Antimicrobial drug use in poultry | |
| Aarestrup et al. | Antimicrobial resistance in swine production | |
| CN111705042B (en) | Pasteurella phage vB _ PmuP _ PS02, phage composition and application thereof | |
| CN103622960B (en) | Compound andrographolidume preparation for veterinary use | |
| CN101744827B (en) | Medicinal composition for killing chicken colibacillosis and preparation method and use thereof | |
| AU2020299061A1 (en) | Quorum-sensing inhibitors and/or postbiotic metabolites and related methods | |
| Wang et al. | Effects of flavomycin, Bacillus licheniformis and enramycin on performance, nutrient digestibility, gut morphology and the intestinal microflora of broilers | |
| CN110709080A (en) | Use of berberine alkaloid preparation in preventing and/or treating infectious diseases | |
| CN109568301A (en) | A kind of gallic acid, Rhein compound prescription preparation method and applications | |
| CN104586777B (en) | Ceftiofur Hydrochloride powder-injection and preparation method and application | |
| CN104586875B (en) | The preparation method of compound tilmicosin enteric coated particles | |
| CN101468057A (en) | Compound Chinese medicine preparation for treating yellow-white dysentery of piglet | |
| CN103918935B (en) | A kind of pet food additives | |
| KR101478110B1 (en) | Ursolic acid having anti-bacterial activity against causative bacteria of porcine respiratory disease complex and uses thereof | |
| Naraghi et al. | Dietary incorporation of Bacillus subtilis and Bacillus licheniformis mixture (DiPro Aqua) Ameliorates growth performance, immune response, and intestinal morphology in rainbow trout | |
| CN102764252A (en) | Application of valnemulin hydrochloride | |
| Toosi et al. | Effects of in ovo injection and inclusion a blend of essential oils and organic acids in high NSPS diets of broiler breeders on performance of them and their offspring | |
| CN104027370B (en) | A kind of livestock and poultry compound containing Plumbago zeylanica and LIJUNJING | |
| CN103250880A (en) | Novel application of trehalose-montmorillonite nano compound as feed additive | |
| CN109985022B (en) | Povidone iodine preparation and its preparing method and use | |
| CN102462686A (en) | Pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry | |
| US20220226394A1 (en) | Algoriphagus sp, bosea sp, brevundimonas sp, desulfovibrio sp, microbacterium sp, sphingomonas sp, and variovorax sp for use in disease prevention and treatment | |
| KR20070039114A (en) | The use of medicinal plants and extracts thereof for the well-being of animals in veterinary medicine and zootechnics | |
| Hamidi-Sofiani et al. | Comparison of Two Different Protocols for the Treatment of Acute Escherichia coli Mastitis in Dairy Cattle | |
| CN113842363A (en) | Preparation process and application of Chinese pulsatilla root particles for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20141215 |
|
| EXPY | Termination of patent right or utility model |